Apigenin and its impact on gastrointestinal cancers

Molecular Nutrition and Food Research

Volumn 57, Issue 1, 2013, Pages 126-144

  Lefort, Émilie C ^a   Blay, Jonathan ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Angiogenesis; Apigenin; Apoptosis; Carcinomas; Metastasis

Indexed keywords

APIGENIN; PLANT EXTRACT;

ANIMAL; APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; FRUIT; GASTROINTESTINAL TUMOR; HUMAN; MEDICINAL PLANT; REVIEW; TUMOR CELL LINE; VEGETABLE;

ANIMALS; APIGENIN; APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FRUIT; GASTROINTESTINAL NEOPLASMS; HUMANS; PLANT EXTRACTS; PLANTS, MEDICINAL; VEGETABLES;

PETROSELINUM CRISPUM;

EID: 84872150379     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200424     Document Type: Review

References (216)

1. Murata, A., Fujino, Y., Pham, T. M., Kubo, T. et al., Prospective cohort study evaluating the relationship between salted food intake and gastrointestinal tract cancer mortality in Japan. Asia Pac. J. Clin. Nutr. 2010, 19, 564-571.
2. Norat, T., Lukanova, A., Ferrari, P., Riboli, E., Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int. J. Cancer 2002, 98, 241-256.
3. Ollberding, N. J., Nomura, A. M., Wilkens, L. R., Henderson, B. E. et al., Racial/ethnic differences in colorectal cancer risk: the multiethnic cohort study. Int. J. Cancer 2011, 129, 1899-1906.
4. de Vere White, R., Hackman, R. M., Kugelmass, J., The dogmas of nutrition and cancer: time for a second (and maybe third) look. Ann. NY Acad. Sci. 2010, 1190, 118-125.
5. Gordaliza, M., Natural products as leads to anticancer drugs. Clin. Transl. Oncol. 2007, 9, 767-776.
6. Vainio, H., Weiderpass, E., Fruit and vegetables in cancer prevention. Nutr. Cancer 2006, 54, 111-142.
7. Key, T. J., Fruit and vegetables and cancer risk. Brit. J. Cancer 2011, 104, 6-11.
8. Sporn, M. B., Dunlop, N. M., Newton, D. L., Smith, J. M., Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 1976, 35, 1332-1338.
9. Khan, N., Mukhtar, H., Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev. 2010, 29, 435-445.
10. Reuter, S., Gupta, S. C., Chaturvedi, M. M., Aggarwal, B. B., Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol. Med. 2010, 49, 1603-1616.
11. Gupta, S. C., Hevia, D., Patchva, S., Park, B. et al., Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antiox. Redox Signal. 2012, 16, 1295-1322.
12. Horinaka, M., Yoshida, T., Shiraishi, T., Nakata, S. et al., The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Therap. 2006, 5, 945-951.
13. Shukla, S., MacLennan, G. T., Flask, C. A., Fu, P. et al., Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 2007, 67, 6925-6935.
14. Lefort, E. C., Blay, J., The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells. Clin. Exp. Metastasis 2011, 28, 337-349.
15. Zhang, Q., Zhao, X. H., Wang, Z. J., Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol. In Vitro 2009, 23, 797-807.
16. Zhang, Q., Zhao, X. H., Wang, Z. J., Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem. Toxicol. 2008, 46, 2042-2053.
17. Turktekin, M., Konac, E., Onen, H. I., Alp, E. et al., Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). J. Med. Food 2011, 14, 1107-1117.
18. Masuelli, L., Marzocchella, L., Quaranta, A., Palumbo, C. et al., Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci. 2011, 16, 1060-1068.
19. Izeradjene, K., Douglas, L., Delaney, A., Houghton, J. A., Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 2005, 24, 2050-2058.
20. Khan, T. H., Sultana, S., Apigenin induces apoptosis in Hep G2 cells: possible role of TNF-alpha and IFN-gamma. Toxicology 2006, 217, 206-212.
21. Zhong, Y., Krisanapun, C., Lee, S. H., Nualsanit, T. et al., Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur. J. Cancer 2010, 46, 3365-3374.
22. King, J. C., Lu, Q. Y., Li, G., Moro, A. et al., Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim. Biophys. Acta 2012, 1823, 593-604.
23. Takagaki, N., Sowa, Y., Oki, T., Nakanishi, R. et al., Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int. J. Oncol. 2005, 26, 185-189.
24. Piantelli, M., Rossi, C., Iezzi, M., La Sorda, R. et al., Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. J. Cell. Physiol. 2006, 207, 23-29.
25. Melstrom, L. G., Salabat, M. R., Ding, X. Z., Milam, B. M. et al., Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 2008, 37, 426-431.
26. Franzen, C. A., Amargo, E., Todorovic, V., Desai, B. V. et al., The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev. Res. 2009, 2, 830-841.
27. Ujiki, M. B., Ding, X. Z., Salabat, M. R., Bentrem, D. J. et al., Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5, 76-84.
28. Wang, W., Heideman, L., Chung, C. S., Pelling, J. C. et al., Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol. Carcinogen. 2000, 28, 102-110.
29. Nurse, P., Universal control mechanism regulating onset of M-phase. Nature 1990, 344, 503-508.
30. Jackman, M., Firth, M., Pines, J., Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J. 1995, 14, 1646-1654.
31. Fang, J., Zhou, Q., Liu, L. Z., Xia, C. et al., Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007, 28, 858-864.
32. Lindenmeyer, F., Li, H., Menashi, S., Soria, C., Lu, H., Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr. Cancer 2001, 39, 139-147.
33. Reddy, K. B., Krueger, J. S., Kondapaka, S. B., Diglio, C. A., Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int. J. Cancer 1999, 82, 268-273.
34. Birt, D. F., Walker, B., Tibbels, M. G., Bresnick, E., Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 1986, 7, 959-963.
35. Johnson, J. L., Rupasinghe, S. G., Stefani, F., Schuler, M. A. et al., Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity. J. Med. Food 2011, 14, 325-333.
36. Khuntawee, W., Rungrotmongkol, T., Hannongbua, S., Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex. J. Chem. Inform. Model. 2012, 52, 76-83.
37. Farah, M., Parhar, K., Moussavi, M., Eivemark, S. et al., 5, 6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-alpha-mediated apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G919-G928.
38. Maldonado-Rojas, W., Olivero-Verbel, J., Potential interaction of natural dietary bioactive compounds with COX-2. J. Mol. Graphics Model. 2011, 30, 157-166.
39. Lee, W. J., Chen, W. K., Wang, C. J., Lin, W. L. et al., Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol. 2008, 226, 178-191.
40. Liu, R. H., Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 2004, 134, 3479S-3485S.
41. Murthy, N. S., Mukherjee, S., Ray, G., Ray, A., Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J. Postgraduate Med. 2009, 55, 45-54.
42. Yao, L. H., Jiang, Y. M., Shi, J., Tomas-Barberan, F. A. et al., Flavonoids in food and their health benefits. Plant Food. Hum. Nutr. 2004, 59, 113-122.
43. Ren, W., Qiao, Z., Wang, H., Zhu, L. et al., Flavonoids: promising anticancer agents. Med. Res. Rev. 2003, 23, 519-534.
44. Birt, D. F., Hendrich, S., Wang, W., Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Therapeut. 2001, 90, 157-177.
45. Harborne, J. B., Williams, C. A., Advances in flavonoid research since 1992. Phytochemistry 2000, 55, 481-504.
46. Patel, D., Shukla, S., Gupta, S., Apigenin and cancer chemoprevention: progress, potential and promise (review). Int. J. Oncol. 2007, 30, 233-245.
47. Huang, W. Y., Cai, Y. Z., Zhang, Y., Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr. Cancer 2010, 62, 1-20.
48. Lepiniec, L., Debeaujon, I., Routaboul, J. M., Baudry, A. et al., Genetics and biochemistry of seed flavonoids. Annu. Rev. Plant Biol. 2006, 57, 405-430.
49. McKay, D. L., Blumberg, J. B., A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytother. Res. 2006, 20, 519-530.
50. Chung, C. S., Jiang, Y., Cheng, D., Birt, D. F., Impact of adenomatous polyposis coli (APC) tumor supressor gene in human colon cancer cell lines on cell cycle arrest by apigenin. Mol. Carcinog. 2007, 46, 773-782.
51. Manach, C., Scalbert, A., Morand, C., Remesy, C. et al., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727-747.
52. Braidot, E., Zancani, M., Petrussa, E., Peresson, C. et al., Transport and accumulation of flavonoids in grapevine (Vitis vinifera L.). Plant Signal. Behav. 2008, 3, 626-632.
53. Ross, J. A., Kasum, C. M., Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 2002, 22, 19-34.
54. Felgines, C., Texier, O., Morand, C., Manach, C. et al., Bioavailability of the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279, G1148-G1154.
55. Nielsen, S. E., Young, J. F., Daneshvar, B., Lauridsen, S. T. et al., Effect of parsley (Petroselinum crispum) intake on urinary apigenin excretion, blood antioxidant enzymes and biomarkers for oxidative stress in human subjects. Br. J. Nutr. 1999, 81, 447-455.
56. Srivastava, J. K., Gupta, S., Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J. Agric. Food Chem. 2007, 55, 9470-9478.
57. Hanske, L., Loh, G., Sczesny, S., Blaut, M. et al., The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats. J. Nutr. 2009, 139, 1095-1102.
58. da Silveira, C. V., Trevisan, M. T., Rios, J. B., Erben, G. et al., Secondary plant substances in various extracts of the leaves, fruits, stem and bark of Caraipa densifolia Mart. Food Chem. Toxicol. 2010, 48, 1597-1606.
59. Czubinski, J., Dwiecki, K., Siger, A., Kachlicki, P. et al., Release of flavonoids from lupin globulin proteins during digestion in a model system. J. Agric. Food Chem. 2012, 60, 1830-1836.
60. Awang-Dennis, V. C., The Herbs of Choice: The Therapeutic Use of Phytochemicals., CRC Press, New York 2006.
61. Hamon, M., Herbal medicine. The chamomiles. Can. Pharm. J. 1989, 122, 612-615.
62. Martens, D., Chamomile: the herb and the remedy. J. Chiropr. Acad. Homeopathy 1995, 6, 15-18.
63. Spicak, V., Subrt, F., [Effect of apigenin on histamine liberation]. Ceskoslovenska fysiologie/Ustredni ustav biologicky 1958, 7, 263-264.
64. Kawai, M., Hirano, T., Higa, S., Arimitsu, J. et al., Flavonoids and related compounds as anti-allergic substances. Allergol. Int. 2007, 56, 113-123.
65. Shantz, L. M., Levin, V. A., Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino acids 2007, 33, 213-223.
66. Sarkar, F. H., Li, Y., Cell signaling pathways altered by natural chemopreventive agents. Mutat. Res. 2004, 555, 53-64.
67. Shukla, S., Gupta, S., Apigenin: a promising molecule for cancer prevention. Pharmaceut. Res. 2010, 27, 962-978.
68. Di Carlo, G., Autore, G., Izzo, A. A., Maiolino, P. et al., Inhibition of intestinal motility and secretion by flavonoids in mice and rats: structure-activity relationships. J. Pharmacy Pharmacol. 1993, 45, 1054-1059.
69. Lohner, K., Schnabele, K., Daniel, H., Oesterle, D. et al., Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol. Nutr. Food Res. 2007, 51, 293-300.
70. Cai, H., Sale, S., Schmid, R., Britton, R. G. et al., Flavones as colorectal cancer chemopreventive agents-phenol-o-methylation enhances efficacy. Cancer Prev. Res. 2009, 2, 743-750.
71. Hoensch, H. P., Oertel, R., Emerging role of bioflavonoids in gastroenterology: especially their effects on intestinal neoplasia. World J. Gastrointest. Oncol. 2011, 3, 71-74.
72. Walle, T., Ta, N., Kawamori, T., Wen, X. et al., Cancer chemopreventive properties of orally bioavailable flavonoids-methylated versus unmethylated flavones. Biochem. Pharmacol. 2007, 73, 1288-1296.
73. Wu, K., Yuan, L. H., Xia, W., Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells. World J. Gastroenterol. 2005, 11, 4461-4464.
74. Wang, W., VanAlstyne, P. C., Irons, K. A., Chen, S. et al., Individual and interactive effects of apigenin analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines. Nutr. Cancer 2004, 48, 106-114.
75. Dulic, V., Stein, G. H., Far, D. F., Reed, S. I., Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell Biol. 1998, 18, 546-557.
76. Foijer, F., Te Riele, H., Check, double check: the G2 barrier to cancer. Cell Cycle 2006, 5, 831-836.
77. Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B. et al., p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 1990, 87, 7555-7559.
78. Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., Enomoto, M. et al., Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 1994, 54, 3011-3020.
79. Mann, B., Gelos, M., Siedow, A., Hanski, M. L. et al., Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 1999, 96, 1603-1608.
80. Rowan, A. J., Lamlum, H., Ilyas, M., Wheeler, J. et al., APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits". Proc. Natl. Acad. Sci. USA 2000, 97, 3352-3357.
81. Groden, J., Thliveris, A., Samowitz, W., Carlson, M. et al., Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66, 589-600.
82. Strouch, M. J., Milam, B. M., Melstrom, L. G., McGill, J. J. et al., The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas 2009, 38, 409-415.
83. Gopinathan, L., Ratnacaram, C. K., Kaldis, P., Established and novel Cdk/cyclin complexes regulating the cell cycle and development. Results Probl. Cell Differ. 2011, 53, 365-389.
84. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
85. Hengartner, M. O., The biochemistry of apoptosis. Nature 2000, 407, 770-776.
86. Kim, B. R., Jeon, Y. K., Nam, M. J., A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells. Food Chem. Toxicol. 2011, 49, 1626-1632.
87. Lee, S. H., Ryu, J. K., Lee, K. Y., Woo, S. M. et al., Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008, 259, 39-49.
88. Kim, R., Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005, 103, 1551-1560.
89. Pereira, W. O., Amarante-Mendes, G. P., Apoptosis: a programme of cell death or cell disposal? Scand. J. Immunol. 2011, 73, 401-407.
90. Abraham, M. C., Shaham, S., Death without caspases, caspases without death. Trends Cell Biol. 2004, 14, 184-193.
91. Varfolomeev, E., Vucic, D., Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 2011, 7, 633-648.
92. Olsson, M., Zhivotovsky, B., Caspases and cancer. Cell Death Different. 2011, 18, 1441-1449.
93. Eskes, R., Desagher, S., Antonsson, B., Martinou, J. C., Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 2000, 20, 929-935.
94. Frisch, S. M., Francis, H., Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994, 124, 619-626.
95. Spencer, S. L., Sorger, P. K., Measuring and modeling apoptosis in single cells. Cell 2011, 144, 926-939.
96. Wajant, H., The Fas signaling pathway: more than a paradigm. Science 2002, 296, 1635-1636.
97. Fuentes-Prior, P., Salvesen, G. S., The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 2004, 384, 201-232.
98. Tawfic, S., Yu, S., Wang, H., Faust, R. et al., Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001, 16, 573-582.
99. Cao, Y., Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 2001, 33, 357-369.
100. Ezekowitz, R. A., Mulliken, J. B., Folkman, J., Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New Engl. J. Med. 1992, 326, 1456-1463.
101. Harris, A. L., Antiangiogenesis for cancer therapy. Lancet 1997, 349 Suppl 2, SII13-SII15.
102. Folkman, J., Long, D. M., Jr., Becker, F. F., Growth and metastasis of tumor in organ culture. Cancer 1963, 16, 453-467.
103. Abdelrahim, M., Konduri, S., Basha, R., Philip, P. A. et al., Angiogenesis: an update and potential drug approaches (review). Int. J. Oncol. 2010, 36, 5-18.
104. Ferrara, N., VEGF and the quest for tumour angiogenesis factors. Nat. Rev. 2002, 2, 795-803.
105. Ferrara, N., VEGF-A: a critical regulator of blood vessel growth. Euro. Cyto. Network 2009, 20, 158-163.
106. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., Vascular endothelial growth factor (VEGF) and its receptors. Faseb. J. 1999, 13, 9-22.
107. Ferrara, N., Gerber, H. P., LeCouter, J., The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
108. Zhong, H., Chiles, K., Feldser, D., Laughner, E. et al., Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
109. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z. et al., Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12, 363-369.
110. Dallas, N. A., Fan, F., Gray, M. J., Van Buren, G., 2nd et al., Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastas. Rev. 2007, 26, 433-441.
111. Rigopoulos, D. N., Tsiambas, E., Lazaris, A. C., Kavantzas, N. et al., Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis. J. Buon. 2010, 15, 107-115.
112. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I. et al., Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
113. Kerbel, R. S., Viloria-Petit, A., Okada, F., Rak, J., Establishing a link between oncogenes and tumor angiogenesis. Mol. Med. 1998, 4, 286-295.
114. Ryan, H. E., Lo, J., Johnson, R. S., HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17, 3005-3015.
115. Semenza, G. L., Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Rev. Cell Develop. Biol. 1999, 15, 551-578.
116. Brahimi-Horn, M. C., Chiche, J., Pouyssegur, J., Hypoxia and cancer. J. Mol. Med. 2007, 85, 1301-1307.
117. Brown, J. M., Giaccia, A. J., The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
118. Vaupel, P., Kallinowski, F., Okunieff, P., Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49, 6449-6465.
119. Opie, L. H., Myocardial ischemia-metabolic pathways and implications of increased glycolysis. Cardiovasc. Drugs Ther. 1990, 4, 777-790.
120. Gatenby, R. A., Gillies, R. J., Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 2007, 39, 1358-1366.
121. Gatenby, R. A., Gillies, R. J., Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891-899.
122. Younes, M., Lechago, L. V., Somoano, J. R., Mosharaf, M. et al., Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996, 56, 1164-1167.
123. Younes, M., Lechago, L. V., Lechago, J., Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin. Cancer Res. 1996, 2, 1151-1154.
124. Anso, E., Zuazo, A., Irigoyen, M., Urdaci, M. C. et al., Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem. Pharmacol. 2010, 79, 1600-1609.
125. Weidemann, A., Johnson, R. S., Biology of HIF-1alpha. Cell Death Different. 2008, 15, 621-627.
126. Clarke, J. F., Young, P. W., Yonezawa, K., Kasuga, M. et al., Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem. J. 1994, 300, 631-635.
127. Melstrom, L. G., Salabat, M. R., Ding, X. Z., Strouch, M. J. et al., Apigenin down-regulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J. Surg. Res. 2011, 167, 173-181.
128. Chambers, A. F., Groom, A. C., MacDonald, I. C., Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563-572.
129. Friedl, P., Wolf, K., Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362-374.
130. Jinka, R., Kapoor, R., Sistla, P. G., Raj, T. A. et al., Alterations in cell-extracellular matrix interactions during progression of cancers. Int. J. Cell Biol. 2012, 2012, 219196.
131. Mott, J. D., Werb, Z., Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell. Biol. 2004, 16, 558-564.
132. Mignatti, P., Rifkin, D. B., Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv. Cancer Res. 2000, 78, 103-157.
133. Sternlicht, M. D., Werb, Z., How matrix metalloproteinases regulate cell behavior. Annual Rev. Cell Develop. Biol. 2001, 17, 463-516.
134. Yoon, S. O., Park, S. J., Yun, C. H., Chung, A. S., Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 2003, 36, 128-137.
135. Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z. et al., Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc. Natl. Acad. Sci. USA 1989, 86, 8207-8211.
136. Kahari, V. M., Saarialho-Kere, U., Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann. Med. 1999, 31, 34-45.
137. Fenton, J. I., Hord, N. G., Flavonoids promote cell migration in nontumorigenic colon epithelial cells differing in Apc genotype: implications of matrix metalloproteinase activity. Nutr. Cancer 2004, 48, 182-188.
138. Birchmeier, C., Birchmeier, W., Gherardi, E., Vande Woude, G. F., Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925.
139. Eder, J. P., Vande Woude, G. F., Boerner, S. A., LoRusso, P. M., Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207-2214.
140. Martin-Belmonte, F., Perez-Moreno, M., Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 2012, 12, 23-38.
141. Makrilia, N., Kollias, A., Manolopoulos, L., Syrigos, K., Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009, 27, 1023-1037.
142. Wang, L., Li, C. L., Yu, W. B., Yin, H. P. et al., Influence of CXCR4/SDF-1 axis on E-cadherin/beta-catenin complex expression in HT29 colon cancer cells. World J. Gastroenterol. 2011, 17, 625-632.
143. Cavallaro, U., Christofori, G., Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. 2004, 4, 118-132.
144. Desgrosellier, J. S., Cheresh, D. A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9-22.
145. Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F. O. et al., Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 2000, 87, 595-600.
146. Aplin, A. E., Howe, A. K., Juliano, R. L., Cell adhesion molecules, signal transduction and cell growth. Curr. Opin. Cell Biol. 1999, 11, 737-744.
147. Hehlgans, S., Haase, M., Cordes, N., Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 2007, 1775, 163-180.
148. Cukierman, E., Pankov, R., Stevens, D. R., Yamada, K. M., Taking cell-matrix adhesions to the third dimension. Science 2001, 294, 1708-1712.
149. Hood, J. D., Cheresh, D. A., Role of integrins in cell invasion and migration. Nat. Rev. 2002, 2, 91-100.
150. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J. et al., The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat. Rev. 2005, 5, 505-515.
151. Hu, X. W., Meng, D., Fang, J., Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis 2008, 29, 2369-2376.
152. Balkwill, F., The significance of cancer cell expression of the chemokine receptor CXCR4. Sem. Cancer Biol. 2004, 14, 171-179.
153. Dittmar, T., Heyder, C., Gloria-Maercker, E., Hatzmann, W. et al., Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin. Exp. Metast. 2008, 25, 11-32.
154. Roussos, E. T., Condeelis, J. S., Patsialou, A., Chemotaxis in cancer. Nat. Rev. Cancer 2011, 11, 573-587.
155. Raman, D., Baugher, P. J., Thu, Y. M., Richmond, A., Role of chemokines in tumor growth. Cancer Lett. 2007, 256, 137-165.
156. Liu, Y., Ji, R., Li, J., Gu, Q. et al., Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J. Exp. Clin. Cancer Res. 2010, 29, 16-25.
157. Muller, A., Homey, B., Soto, H., Ge, N. et al., Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
158. Matsusue, R., Kubo, H., Hisamori, S., Okoshi, K. et al., Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann. Surg. Oncol. 2009, 16, 2645-2653.
159. Scotton, C., Milliken, D., Wilson, J., Raju, S. et al., Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br. J. Cancer 2001, 85, 891-897.
160. Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J. et al., Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 2000, 6, 3530-3535.
161. Teicher, B. A., Fricker, S. P., CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16, 2927-2931.
162. Lataillade, J. J., Domenech, J., Le Bousse-Kerdiles, M. C., Stromal cell-derived factor-1 (SDF-1)\CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Europ. Cyto. Network 2004, 15, 177-188.
163. Russell, H. V., Hicks, J., Okcu, M. F., Nuchtern, J. G., CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J. Pediat. Surg. 2004, 39, 1506-1511.
164. Mongan, J. P., Fadul, C. E., Cole, B. F., Zaki, B. I. et al., Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin. Colorectal Cancer 2009, 8, 100-105.
165. Ding, Y. L., Fu, Q. Y., Tang, S. F., Zhang, J. L. et al., [Effect of stromal cell-derived factor-1 and its receptor CXCR4 on liver metastasis of human colon cancer]. Zhonghua wai ke za zhi [Chinese Journal of Surgery] 2009, 47, 210-213.
166. Ottaiano, A., Franco, R., Aiello Talamanca, A., Liguori, G. et al., Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 2006, 12, 2795-2803.
167. Burns, J. M., Summers, B. C., Wang, Y., Melikian, A. et al., A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201-2213.
168. Luker, K. E., Lewin, S. A., Mihalko, L. A., Schmidt, B. T. et al., Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012, 31, 4750-4758.
169. Zheng, K., Li, H. Y., Su, X. L., Wang, X. Y. et al., Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 2010, 29, 31-45.
170. Salmaggi, A., Maderna, E., Calatozzolo, C., Gaviani, P. et al., CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol. Ther. 2009, 8, 1608-1614.
171. Liu, Z., Christensson, M., Forslow, A., De Meester, I. et al., A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J. Immunol. 2009, 183, 3616-3624.
172. Matteucci, E., Giampietro, O., Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr. Med. Chem. 2009, 16, 2943-2951.
173. Christopherson, K. W., 2nd, Hangoc, G., Broxmeyer, H. E., Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 2002, 169, 7000-7008.
174. Kikkawa, F., Kajiyama, H., Shibata, K., Ino, K. et al., Dipeptidyl peptidase IV in tumor progression. Biochim. Biophys. Acta 2005, 1751, 45-51.
175. Moehrle, M. C., Schlagenhauff, B. E., Klessen, C., Rassner, G., Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study. J. Cutan. Pathol. 1995, 22, 241-247.
176. Sun, Y. X., Pedersen, E. A., Shiozawa, Y., Havens, A. M. et al., CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin. Exp. Metastasis 2008, 25, 765-776.
177. Lambeir, A. M., Proost, P., Durinx, C., Bal, G. et al., Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 2001, 276, 29839-29845.
178. Shioda, T., Kato, H., Ohnishi, Y., Tashiro, K. et al., Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA 1998, 95, 6331-6336.
179. Meyer, H., Bolarinwa, A., Wolfram, G., Linseisen, J., Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metabol. 2006, 50, 167-172.
180. Cao, J., Zhang, Y., Chen, W., Zhao, X., The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. Br. J. Nutr. 2010, 103, 249-255.
181. Hollman, P. C., de Vries, J. H., van Leeuwen, S. D., Mengelers, M. J. et al., Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 1995, 62, 1276-1282.
182. Manach, C., Morand, C., Texier, O., Favier, M. L. et al., Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J. Nutr. 1995, 125, 1911-1922.
183. Graefe, E. U., Wittig, J., Mueller, S., Riethling, A. K. et al., Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 2001, 41, 492-499.
184. Scalbert, A., Williamson, G., Dietary intake and bioavailability of polyphenols. J. Nutr. 2000, 130, 2073S-2085S.
185. Srivastava, J. K., Gupta, S., Extraction, characterization, stability and biological activity of flavonoids isolated from chamomile flowers. Mol. Cell. Pharmacol. 2009, 1, 138-153.
186. Nemeth, K., Plumb, G. W., Berrin, J. G., Juge, N. et al., Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr. 2003, 42, 29-42.
187. Pforte, H., Hempel, J., Jacobasch, G., Distribution pattern of a flavonoid extract in the gastrointestinal lumen and wall of rats. Food/Nahrung 1999, 43, 205-208.
188. Wan, L., Guo, C., Yu, Q., Li, Y. et al., Quantitative determination of apigenin and its metabolism in rat plasma after intravenous bolus administration by HPLC coupled with tandem mass spectrometry. J. Chromatogr. 2007, 855, 286-289.
189. Gradolatto, A., Basly, J. P., Berges, R., Teyssier, C. et al., Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metabol. Disposition Biological Fate of Chem. 2005, 33, 49-54.
190. Crespy, V., Morand, C., Manach, C., Besson, C. et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am. J. Physiol. 1999, 277, G120-G126.
191. Andlauer, W., Kolb, J., Furst, P., Absorption and metabolism of genistin in the isolated rat small intestine. FEBS Lett. 2000, 475, 127-130.
192. Walle, U. K., Galijatovic, A., Walle, T., Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. 1999, 58, 431-438.
193. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J. et al., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5 homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
194. Ng, S. P., Wong, K. Y., Zhang, L., Zuo, Z. et al., Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J. Pharm. Pharmaceut. Sci. 2004, 8, 1-9.
195. Hao, X., Cheng, G., Yu, J. E., He, Y. et al., Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats. Pharmazie 2005, 60, 477-478.
196. Cai, H., Boocock, D. J., Steward, W. P., Gescher, A. J., Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemotherapy Pharmacol. 2007, 60, 257-266.
197. Xiao, J., Cao, H., Chen, T., Yang, F. et al., Molecular property-binding affinity relationship of flavonoids for common rat plasma proteins in vitro. Biochimie 2011, 93, 134-140.
198. Yang, F., Zhao, Y., Kai, G., Xiao, J., Interaction of dietary flavonoids with gamma-globulin: molecular property-binding affinity relationship aspect. Food Funct. 2011, 2, 137-141.
199. Diniz, A., Escuder-Gilabert, L., Lopes, N. P., Villanueva-Camanas, R. M. et al., Characterization of interactions between polyphenolic compounds and human serum proteins by capillary electrophoresis. Analyt. Bioanal. Chem. 2008, 391, 625-632.
200. Cao, H., Chen, L., Xiao, J., Binding citrus flavanones to human serum albumin: effect of structure on affinity. Mol. Biol. Reports 2011, 38, 2257-2262.
201. Xiao, J., Cao, H., Wang, Y., Yamamoto, K. et al., Structure-affinity relationship of flavones on binding to serum albumins: effect of hydroxyl groups on ring A. Mol. Nutr. Food Res. 2010, 54, S253-S260.
202. Xiao, J., Suzuki, M., Jiang, X., Chen, X. et al., Influence of B-ring hydroxylation on interactions of flavonols with bovine serum albumin. J. Agric. Food Chem. 2008, 56, 2350-2356.
203. Huang, Y., Cui, L. J., Wang, J. M., Huo, K. et al., Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme. Europ. J. Med. Chem. 2011, 46, 6039-6045.
204. Chen, D., Chen, M. S., Cui, Q. C., Yang, H. et al., Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci. 2007, 12, 1935-1945.
205. Ueda, H., Yamazaki, C., Yamazaki, M., A hydroxyl group of flavonoids affects oral anti-inflammatory activity and inhibition of systemic tumor necrosis factor-alpha production. Biosci. Biotechnol. Biochem. 2004, 68, 119-125.
206. Das, A., Banik, N. L., Ray, S. K., Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 2010, 116, 164-176.
207. Torkin, R., Lavoie, J. F., Kaplan, D. R., Yeger, H., Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol. Cancer Therapeut. 2005, 4, 1-11.
208. Hussain, A. R., Khan, A. S., Ahmed, S. O., Ahmed, M. et al., Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Proliferation 2010, 43, 170-183.
209. Seo, H. S., Ju, J. H., Jang, K., Shin, I., Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor alpha-negative breast cells. Nutr. Res. 2011, 31, 139-146.
210. Chan, L. P., Chou, T. H., Ding, H. Y., Chen, P. R. et al., Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim. Et Biophys. Acta 2012, 1820, 1081-1091.
211. Singh, P., Mishra, S. K., Noel, S., Sharma, S. et al., Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PloS One 2012, 7, e31964.
212. Yang, L., Allred, K. F., Geera, B., Allred, C. D. et al., Sorghum phenolics demonstrate estrogenic action and induce apoptosis in nonmalignant colonocytes. Nutr. Cancer 2012, 64, 419-427.
213. Tatsuta, A., Iishi, H., Baba, M., Yano, H. et al., Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin. Exp. Metastasis 2001, 18, 657-662.
214. Ernst, E., Cassileth, B. R., The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998, 83, 777-782.
215. Tough, S. C., Johnston, D. W., Verhoef, M. J., Arthur, K. et al., Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Alternat. Ther. Health Med. 2002, 8, 54-64.
216. Tascilar, M., de Jong, F. A., Verweij, J., Mathijssen, R. H., Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006, 11, 732-741.